{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-028853","form_type":"8-K","ticker":"NUVL","cik":"0001861560","company_name":"Nuvalent, Inc.","filed_at":"2022-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.495836+00:00","generated_at":"2026-06-24T01:35:58.343431+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Nuvalent reports Q2 2022 net loss of $18.5M; pipeline on track with NVL-520 data expected H2 2022","bullets":["Net loss of $18.5M ($0.38 per share); cash, equivalents and marketable securities $257.0M expected to fund operations into 2024.","R&D expenses $13.6M, G&A $5.2M for Q2 2022.","Preliminary dose-escalation data from Phase 1 ARROS-1 trial (NVL-520 for ROS1+ NSCLC) anticipated in H2 2022.","Dosing initiated in Phase 1 ALKOVE-1 trial (NVL-655 for ALK+ NSCLC); new preclinical data presented at WCLC 2022.","On track to select two additional development candidates in H2 2022 for ALK compound resistance mutations and HER2 Exon 20 insertions."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-028853","json":"https://secwatch.observer/filing/0001564590-22-028853.json","markdown":"https://secwatch.observer/filing/0001564590-22-028853.md","text":"https://secwatch.observer/filing/0001564590-22-028853.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1861560/000156459022028853/0001564590-22-028853-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1861560/000156459022028853/nuvl-8k_20220810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:35:58.343431+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}